Download Strategies to Switch Antidepressants

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Strategies to Switch
Antidepressants
Brittany Parmentier, PharmD
PGY2 Behavioral Care Resident
Butler University/Community Health Network
This speaker has no actual or potential conflicts of interest to disclose in
relation to this presentation.
Abbreviations
AD – antidepressant
SSRI – selective serotonin reuptake inhibitor
SNRI – serotonin norepinephrine reuptake inhibitor
TCA – tricyclic antidepressant
MAOI – monoamine oxidase inhibitor
Need for Switch
27.5% of STAR*D patients achieved
remission with 1st treatment
50% of depression patients respond to
1st treatment
35-50% of responders still have
residual symptoms
Intolerance to side effects
Trivedi MH e al. Am J Psychiatry. 2006;163:28-40.
Fava M et al. Psychiatr Clin N Am. 2003;26:457-494.
Key Points before Switching
Optimize
dose
Adequate
duration
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (3 rd ed). Oct 2010. Available
at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed July 30, 2015.
General Considerations
Individualized therapy for each patient
Variations in acute and ambulatory practice
Limited data comparing one strategy to
another
Jefferson JW. J Clin Psychiatry. 2008;69(Suppl E1):14-18.
Switching Effects
Serotonin Syndrome
• Sweating
• Insomnia
• Tremor
• Akathisia
Antidepressant Discontinuation
Zerumsky K et al. P&T. 2005;30(12):740-747.
•
•
•
•
•
•
Flu-like symptoms
Insomnia
Nausea
Imbalance
Sensory disturbances
Hyperarousal (anxiety/agitation)
Between SSRIs
SSRI (except fluoxetine)  SSRI
• Direct switch to equivalent dose
• Direct switch to lower new dose of new SSRI
Fluoxetine  Other SSRI
• Stop fluoxetine, 4-7 day washout with no
antidepressant, start new SSRI at low dose
Marangell. J Clin Psychiatry. 2001;62(Suppl 18):12-7.
Zerumsky K et al. P&T. 2005;30(12):740-747.
SSRI Dose Equivalency
SSRI
Fluoxetine
Paroxetine
Citalopram
Escitalopram
Sertraline
Fluvoxamine
Hayasaka Y et al. J Affect Disord. 2015;180:179-184.
Dose
20 mg
20 mg
20 mg
10 mg
50 mg
50 mg
SSRI to SNRI
SSRI  duloxetine
• Direct switch to duloxetine 60mg daily
• Start duloxetine 60mg and taper SSRI down
SSRI  venlafaxine
• Direct switch to low dose venlafaxine (37.5 mg –
75mg)
• Cross-taper
Marangell. J Clin Psychiatry. 2001;62(Suppl 18):12-7.
Jefferson JW. J Clin Psychiatry. 2008;69(Suppl E1):14-18.
SNRI to SSRI
Venlafaxine  SSRI
• Direct switch to therapeutic SSRI dose
• Cross-taper
Duloxetine  SSRI
• Direct switch to therapeutic SSRI dose
• Cross-taper
Marangell. J Clin Psychiatry. 2001;62(Suppl 18):12-7.
Jefferson JW. J Clin Psychiatry. 2008;69(Suppl E1):14-18.
Bupropion, Mirtazapine, and TCAs
To/from
another agent
Marangell. J Clin Psychiatry. 2001;62(Suppl 18):12-7.
Jefferson JW. J Clin Psychiatry. 2008;69(Suppl E1):14-18.
Cross-taper
MAOIs – High Risk for Toxicity
MAOI  MAOI
MAOI  Other antidepressant
Other antidepressant (except fluoxetine)  MAOI
• Stop medication, 2 week washout with no AD, start new AD
Fluoxetine  MAOI
• Stop fluoxetine, 5 week washout with no AD, start MAOI
Marangell. J Clin Psychiatry. 2001;62(Suppl 18):12-7.
Jefferson JW. J Clin Psychiatry. 2008;69(Suppl E1):14-18.
Assessment Question
When would it be most appropriate to do a direct
switch from a therapeutic dose of old AD to a
therapeutic dose of new AD?
A. Imipramine  tranylcypromine
B. Escitalopram  nortriptyline
C. Citalopram  sertraline
D. Venlafaxine  phenelzine
Assessment Question
When would it be most appropriate to do a direct
switch from a therapeutic dose of old AD to a
therapeutic dose of new AD?
A. Imipramine  tranylcypromine
B. Escitalopram  nortriptyline
C. Citalopram  sertraline
D. Venlafaxine  phenelzine
Strategies to Switch
Antidepressants
Brittany Parmentier, PharmD
PGY2 Behavioral Care Resident
Butler University/Community Health Network
[email protected]
Related documents